(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 17.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Ionis Pharmaceuticals's revenue in 2025 is $705,138,000.On average, 9 Wall Street analysts forecast IONS's revenue for 2025 to be $102,574,721,534, with the lowest IONS revenue forecast at $96,663,298,558, and the highest IONS revenue forecast at $109,717,485,634. On average, 10 Wall Street analysts forecast IONS's revenue for 2026 to be $135,702,026,230, with the lowest IONS revenue forecast at $116,839,107,420, and the highest IONS revenue forecast at $154,102,039,625.
In 2027, IONS is forecast to generate $180,520,395,083 in revenue, with the lowest revenue forecast at $64,221,767,888 and the highest revenue forecast at $220,659,000,013.